| Document |
Document Title |
|
WO/2023/063784A1 |
The present invention relates to a composition for combination therapy, comprising a 2,3,5-substituted thiophene compound, has an activity of inhibiting cancer cells associated with leukemia that is superior to that of treatment individu...
|
|
WO/2023/062222A1 |
The present invention relates to an association of a Faecalibacterium prausnitzii bacterial strain deposited to the CNCM under the accession number I-4573; and at least one immune checkpoint inhibitor, in particular at least one monoclon...
|
|
WO/2023/061554A1 |
The present invention relates to the use of 5-Hydroxymethylfurfural (5-HMF) for prevention and/or treatment of conditions or diseases, respectively, associated with mitochondrial dysfunction as well as corresponding treatment methods.
|
|
WO/2023/062159A1 |
The present invention relates to the association of at least one bacterial strain of the species Enterococcus faecalis and an anti-inflammatory agent, a composition comprising same, and the uses thereof as a medicament, in particular for...
|
|
WO/2023/064847A1 |
Provided herein are methods of treating a trauma patient, the method including: (a) administering a HDAC inhibitor to the trauma patient; and (b) administering a GRK2 inhibitor to the trauma patient, wherein the treatment prevents, reduc...
|
|
WO/2023/064819A1 |
Provided herein are methods of treating a subject having epidermolysis bullosa, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amniotic fluid substantially free of en...
|
|
WO/2023/062516A1 |
Preparations and forms of 2-deoxy-D-glucose (2-DG) for use in the treatment or prevention of a viral disease, collaboratively in the treatment of cancer with other cancer treatments, and in a natural preparation with natural minerals to ...
|
|
WO/2023/062354A2 |
The present disclosure relates to nanoparticles and nanoparticulate compositions; methods of preparing such nanoparticles and nanoparticulate compositions; and associated methods of medical treatment and uses of such nanoparticles and na...
|
|
WO/2023/057613A1 |
The present invention relates to benzimidazole derivatives and pharmaceutical compositions comprising such benzimidazole derivatives, for use in the treatment or prevention of a histiocytosis or a craniopharyngioma.
|
|
WO/2023/057386A1 |
The present application relates to compositions comprising sialic acid and/or fucose to enhance cognitive function by promoting differentiation of oligodendrocyte precursor cells into mature, myelinating oligodendrocytes.
|
|
WO/2023/059728A1 |
The present invention concerns methods of treating and/or preventing sexual dysfunction, wherein the sexual dysfunction is associated with one or more mental health conditions, the method using a pharmaceutical composition comprising the...
|
|
WO/2023/060227A1 |
The present invention provides methods for selecting a cancer patient who is YAP1 and/or TAZ nuclear positive, and methods for treating cancer in a cancer patient who is YAP1 and/or TAZ nuclear positive, and administering to the patient ...
|
|
WO/2023/058987A1 |
The present invention relates to a pharmaceutical composition for preventing or treating viral infectious diseases, containing efavirenz and fluoxetine as active ingredients. It has been identified that when a complex, mixture or combina...
|
|
WO/2023/057819A1 |
The disclosure is in part directed to a method of treating a cancer in a patient in need thereof, comprising administering to the patient an effective amount of a HSF1 pathway inhibitor, wherein the cancer comprises solid tumors identifi...
|
|
WO/2023/057882A1 |
This disclosure relates to a method for treating cancer by administering a compound of Formula (I) in combination with a PD-1 axis binding antagonist to a subject in need thereof.
|
|
WO/2023/059703A1 |
Provided are methods for treating various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA), with the JAK1 inhibitor, upadacitinib free base or pharmaceutically acceptable salt thereof. In various aspects, ...
|
|
WO/2023/057879A1 |
Methods and products for treating a subject diagnosed with an autism spectrum disorder, an intellectual disability, an anxiety disorder, a mood disorder, a disorder of social interaction, irritability, aggression, self-injurious behavior...
|
|
WO/2023/057109A1 |
The present invention relates to the medical-pharmaceutical field of therapy of inflammatory diseases of in particular the human ear and more particularly of various forms of otitis such as otitis media. The invention particularly relate...
|
|
WO/2023/059148A1 |
The present invention relates to use of 2-chloro-N,N-diethylethylamine hydrochloride for improving anti-cancer treatment, and has the benefits of killing cancer cells by alkylating a DNA base using a nitrogen mustard-based compound of ch...
|
|
WO/2023/056972A1 |
Provided is the use of clostridium ghonii in combination with a tumor angiogenesis inhibitor in the preparation of a pharmaceutical product for treating tumors. Further provided is a drug for treating tumors, and active ingredients of th...
|
|
WO/2023/056897A1 |
Provided is the use of a c-Abl inhibitor in the preparation of a drug for preventing and/or treating amyotrophic lateralizing sclerosis. Provided are the use of a c-Abl protein as a target in screening a drug for preventing and/or treati...
|
|
WO/2023/060094A1 |
Provided herein are compositions and methods of modulating an aversive taste of active pharmaceutical ingredients (API) in a medicament, nutrient, and/or a dietary supplement via inhibition of a purinergic receptor. Additionally provided...
|
|
WO/2023/051923A1 |
The present invention relates to a condensation product, obtained by the reaction of a phenolic compound and a carbonyl compound, or a pharmaceutical composition comprising the same for use in a method for the prevention or treatment of ...
|
|
WO/2023/050297A1 |
A topical pharmaceutical composition, comprising a blood volume expander, a non-synergistic drug, and a proper amount of solvent. The pharmacological concentration of the expander is less than or equal to 30%, preferably 2-30%, and more ...
|
|
WO/2023/054704A1 |
The present invention addresses the problem of providing technology for dispersing a water-soluble compound in oil that can be applied to pharmaceuticals.　The present invention provides a method for producing a lecithin-water-soluble c...
|
|
WO/2023/054706A1 |
The present invention provides a conjugate of an antibody and a functional substance, said conjugate having excellent desired properties, or a salt thereof. More particularly, the present invention provides a conjugate of an antibody and...
|
|
WO/2023/052520A1 |
The present invention relates to a condensation product, obtained or obtainable by reaction of phenol, formaldehyde, sulfuric acid and urea, for use in a method for the treatment or prevention of a condition associated with one or more p...
|
|
WO/2023/056433A1 |
Provided herein are compositions comprising a composite of peptide amphiphile nanofibers and hyaluronic acid (HA) particles, and methods of preparation and use thereof, such as for repair of a cartilage or osteochondral defects.
|
|
WO/2023/054423A1 |
The disclosure provides uses of multispecific antigen-binding molecules that targets human DLL3 for the treatment of cancers.
|
|
WO/2023/051925A1 |
The present invention relates to a condensation product, obtained by the reaction of a phenolic compound and a carbonyl compound, for use in a method for the treatment or prevention of a condition associated with one or more protease(s) ...
|
|
WO/2023/055904A1 |
Compounds capable of binding to and inhibiting the activity of RAS protein are described herein along with compositions and methods useful for treating RAS protein related diseases such as, for example, cancer.
|
|
WO/2023/054578A1 |
The present invention pertains to a pharmaceutical composition for the prevention or treatment of respiratory diseases, particularly, inflammatory respiratory diseases, the pharmaceutical composition containing, as an active ingredient, ...
|
|
WO/2023/053272A1 |
The disclosure provides uses of multispecific antigen-binding molecules that targets human DLL3 for the treatment of cancers.
|
|
WO/2023/054547A1 |
Provided is a novel cancer treatment method which exhibits a remarkably excellent antitumor effect with little side effects. An antitumor agent includes a biphenyl compound for use in a treatment of a subject having cancer. The treatment...
|
|
WO/2023/052517A1 |
The present invention relates to a condensation product, obtained or obtainable by the reaction of phenol, formaldehyde, sulfuric acid and urea, or a pharmaceutical composition comprising the same for use in a method for the prevention o...
|
|
WO/2023/056413A1 |
Generally, the present disclosure contemplates engineered vectors, organisms (e.g., bacteria or bacteriophage) containing the same, and methods for treating the gut of mammalian species by providing the organism containing the engineered...
|
|
WO/2023/050909A1 |
Disclosed is the use of a CGA gene as a target in the preparation of a drug for diagnosing and treating drug-resistant solid tumors. Specifically disclosed is the use of the gene and/or a protein as a target in diagnosing and treating dr...
|
|
WO/2023/052682A1 |
The invention relates to the use of an activating AR gene alteration as a biomarker for identifying prostate cancer patients who have a higher probability to be responsive to the treatment with a CYP11A1 inhibitor. The invention also rel...
|
|
WO/2023/054626A1 |
Provided is a cyclopropanamide derivative. A compound represented by formula (1) [wherein: n represents an integer of 0, 1, 2 or 3; ring A represents (1) 4-pyridyl which may be substituted with 1 to 4 substituents, or (2) phenyl which is...
|
|
WO/2023/051725A1 |
A pharmaceutical combination and use thereof. The pharmaceutical combination comprises a substance X and a substance Y. When endocrine therapy is used in combination with CDK4/6 inhibitors to treat a breast cancer that has drug resistanc...
|
|
WO/2023/045778A1 |
A self-dispersed particle system, and preparation and an application thereof. By means of the self-dispersed particle system, a combination of slightly soluble or insoluble compounds can interact without the assistance of an additional c...
|
|
WO/2023/049530A1 |
The invention described herein relates to nanoparticles and micelle constructs comprising a polykinase inhibitor and/or a chemotherapeutic agent and methods of using the same to treat cancer.
|
|
WO/2023/049721A1 |
Provided herein are compounds, pharmaceutical compositions, and methods of use thereof, including methods of treating metabolic disorders and psychiatric disorders and diseases associated with metabolic disorders. For example, provided h...
|
|
WO/2023/048230A1 |
The purpose of the present invention is to provide a method having a superior anti-tumor effect. [Solution] A therapy device kit having an anti-cancer drug for inducing immunogenic cell death and an administration device capable of admin...
|
|
WO/2023/049363A1 |
Provided herein are methods of treating cancer comprising a KRAS G12C mutation in a patient comprising administering to the patient sotorasib and afatinib in amounts effective to treat the cancer.
|
|
WO/2023/048748A1 |
Compositions comprising an active agent and a decoy molecule and methods for treating pain by topically administering such compositions are described herein. The compositions may be powdered. Compositions include a decoy molecule with a ...
|
|
WO/2023/048506A1 |
The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a carnitine acylcarnitine carrier (CAC) inhibitor and an anticancer agent, and an anticancer adjuvant. The composition comprising...
|
|
WO/2023/047403A1 |
Provided herein is an ophthalmic composition, comprising an aqueous solution, comprising (i) a pharmaceutically effective amount of a phosphorylcholine-tuftsin conjugate, (ii) between 0.1 and 5% weight per weight (w/w) of a viscosity enh...
|
|
WO/2023/048231A1 |
The problem of the present invention is to provide a medicine for killing tumor cells, said medicine having few side effects. The present invention provides a medicine for killing tumor cells, said medicine containing: a conjugate of a s...
|
|
WO/2023/047203A1 |
Present invention relates to combination comprising omzotirome and one or more antidiabetic agent, antihypertensive agent and/or anti-dyslipidemic agent and use of such combination for managing cardio-metabolic based chronic diseases by ...
|
